Building Inhibitors of Signal Transduction Pathways

For pdf of product catalogue click download

ABT-263(Navitoclax)RequestCatalog# A-1001   

        ABT-263 is a Bcl-2 family inhibitor, in clinical trials

ABT-737RequestCatalog# A-1002   

        ABT-737 is a Bcl-2 family inhibitor, pre-clinical

ABT-888RequestCatalog# A-1003   

        ABT-888 is a potent inhibitor of PARP-1 and PARP-2 (potency =5nM in vitro)

AEE-788RequestCatalog# A-1105   

        AEE-788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor

AG-013736 (Axitinib)RequestCatalog# A-1156   

        Axitinib (also known as AG-013736) is a small molecule tyrosine kinase inhibitor. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and cKIT (CD117).

AP-23573RequestCatalog# A-1004   

        AP-23573 (MK-8669, Deforolimus) is an mTOR inhibitor

AP-24534 (Ponatinib)RequestCatalog# A-1158   

        AP-24534 (Ponatinib), a novel inhibitor of BCR/ABL, FGFR, VEGFR.

AP-26113RequestCatalog# A-1157   

        AP-26113 is a novel potent ALK inhibitor.

AP-26113RequestCatalog# A-1157   

        AP-26113 is a novel orally available, and potent dual kinase inhibitor of ALK and EGFR.

ARQ-197(Tivantinib)RequestCatalog# A-1109   

        ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase

ARRY-380RequestCatalog# A-1177   

        ARRY-380 is an orally active, reversible and selective ErbB-2 inhibitor

AS-703026RequestCatalog# A-1005   

        AS-703026 is an MEK inhibitor.

ASA-404RequestCatalog# A-1142   

        ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA)

ASP-3026RequestCatalog# A-1171   

        ASP-3026 is an ALK inhibitor.

AT-406RequestCatalog# A-1207   

        AT-406 is an orally-active XIAP inhibitor.

AV-951(Tivozanib)RequestCatalog# A-1118   

        AV-951 is a potent and selective inhibitor of VEGFR-1, 2 & 3 kinases.

AZD-0530RequestCatalog# A-1006   

AZD-1480RequestCatalog# A-1135   

        AZD-1480 is a potent JAK2 inhibitor (IC50 = 260 pM)

AZD-2014RequestCatalog# A-1090   

        AZD-2014 is a mTOR inhibitor in clinical trials

AZD-2281 (Olaparib)RequestCatalog# A-1125   

        Highly potent, oral and selective inhibitor of poly(ADP-ribose) polymerase (PARP)

AZD-4547RequestCatalog# A-1174   

        AZD-4547 is a FGFR inhibitor.

AZD-5363RequestCatalog# A-1183   

        AZD5363 is an AKT inhibitor.

AZD-6244(ARRY-142886, Selumetinib)RequestCatalog# A-1007   

        AZD-6244 is a novel inhibitor of MEK1/2 kinases,effectively inhibited the proliferation of acute biphenotypic leukemia MV4-11 and acute monocytic leukemia MOLM13 cells

AZD-7762RequestCatalog# A-1116   

        AZD-7762 is a checkpoint kinase inhibitor in clinical trials.

AZD-8055RequestCatalog# A-1008   

        AZD-8055 is an mTORC1/C2 inhibitor with an IC50 of 0.8 nmol/L, in clinical trials

AZD-8931RequestCatalog# A-1197   

        AZD8931 is a potent, reversible, small-molecule inhibitor against ErbB1 , ErbB2 and ErbB3 kinases.

b-AP15RequestCatalog# A-1194   

        b-AP15 is a novel inhibitor of proteasome activity, with a different mechanism of action than the available and widely used proteasome inhibitors such as bortezomib.

BAY-869766 (RDEA-119)RequestCatalog# A-1036   

        BAY-869766 (RDEA-119) is a potent and highly selective MEK Inhibitor

BAY73-4506 (Regorafenib)RequestCatalog# A-1112   

        Regorafenib (BAY73-4506) is an oral multikinase inhibitor, including B-Raf (IC50, 69 nM), c-KIT (IC 50, 17 nM), VEGFR2 (IC50, 40nM)

BAY87-2243RequestCatalog# A-1178   

BEZ-235RequestCatalog# A-1009   

        BEZ-235 is a PI3K/mTOR inhibitor in clinical trials

BGJ-398RequestCatalog# A-1143   

        NVP-BGJ398 is an FGFR kinase inhibitor

BGT-226RequestCatalog# A-1070   

        BGT-226 is a PI3K/mTOR inhibitor in clinical trials

BI-2536RequestCatalog# A-1010   

        BI-2536 is a potent inhibitor of the mitotic kinase plk1. It causes mitotic arrest and induces apoptosis in human cell lines of various origin and has progressed into clinical trials (1,2).

BI-6727RequestCatalog# A-1187   

        BI6727 is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity.

BIBW-2992 (Tovok)RequestCatalog# A-1122   

        BIBW-2992 (Tovok) is an irreversible, potent, orally bioavailable inhibitor of EGFR and HER2 ...

BKM-120RequestCatalog# A-1108   

        BKM-120 is a PI3K inhibitor in clinical trials.

BMS-536924RequestCatalog# A-1011   

        BMS-536924 is an inhibitor of the IGF-IR (IC50 = 100 nM), InsR and fokal adhesion kinase

BMS-599626RequestCatalog# A-1012   

        BMS-599626 is a pan-HER Kinase Inhibitor

BMS-754807RequestCatalog# A-1013   

        BMS-754807 is an IGF-1R inhibitor, in phase I clinical trials

BMS-777607RequestCatalog# A-1155   

        BMS-777607 is a Small-Molecule Met Kinase Inhibitor.

BMS-863233(XL-413)RequestCatalog# A-1072   

        BMS-863233 (XL-413) is a CDC7 inhibitor in clinical trials.

BMS-911543RequestCatalog# A-1175   

        BMS-911543 is a JAK2 Inhibitor.

Bortezomib (PS-341)RequestCatalog# A-1014   

        Bortezomib (PS-341) is a proteasome inhibitor

Brivanib(BMS-582664)RequestCatalog# A-1160   

        Brivanib(BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.

BYL-719RequestCatalog# A-1214   

        BYL719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.

CAL-101RequestCatalog# A-1138   

        CAL-101 is an Oral Delta Isoform-Selective PI3 Kinase Inhibitor.

Cediranib(AZD-2171)RequestCatalog# A-1161   

        Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

CEP-18770RequestCatalog# A-1095   

        CEP-18770 is a Proteasome inhibitor in clinical trials

CEP-9722RequestCatalog# A-1188   

        CEP-9722 is a PARP inhibitor.

CH-5132799RequestCatalog# A-1215   

        CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3K汐 (IC(50)=0.014 米M).

CH-5424802RequestCatalog# A-1176   

        CH5424802 is a potent and selective ALK inhibitor

CHR-3996RequestCatalog# A-1082   

        CHR-3996 is a HDAC inhibitor in clinical trials

CI-1033RequestCatalog# A-1015   

        CI-1033is an inhibitor of EGFR , HER-2 and ErbB-4

CI-1040(PD 184352)RequestCatalog# A-1064   

        ATP-noncompetitive MEK inhibitor

CyclopamineRequestCatalog# A-1057   

        Cyclopamine is a hegehog pathway inhibitor.

EMD-1214063RequestCatalog# A-1087   

        EMD-1214063 is a c-Met inhibitor in clinical trials

GDC-0068RequestCatalog# A-1205   

        GDC-0068 is a highly selective ATP-competitive pan-Akt inhibitor that inhibits all three isoforms of Akt with IC50 values of 5 to 30 nM.

GDC-0449RequestCatalog# A-1113   

        GDC-0449 is an orally-administered small molecule antagonist of Hedgehog signaling pathway.

GDC-0623RequestCatalog# A-1181   

        GDC-0623 is an MEK inhibitor.

GDC-0941RequestCatalog# A-1017   

        GDC-0941 is a PI3K inhibitor

GDC-0973 (XL-518)RequestCatalog# A-1180   

        GDC-0973(XL-518) is an MEK inhibitor.

GDC-0980RequestCatalog# A-1069   

        GDC-0980 is a PI3K/mTOR inhibitor in clinical trials

Gleevec (STI-571)RequestCatalog# A-1018   

        Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec,

GSK-1120212(JTP-74057)RequestCatalog# A-1083   

        GSK-1120212 is a MEK inhibitor in clinical trials

GSK-1363089 (XL-880)RequestCatalog# A-1086   

        GSK-1363089 (XL-880) is a c-Met inhibitor in clinical trials

GSK-2126458RequestCatalog# A-1067   

        GSK-2126458 is a PI3K/mTOR inhibitor in clinical trials

GSK-2141795RequestCatalog# A-1019   

GSK-2256098RequestCatalog# A-1078   

        GSK-2256098 is a FAK inhibitor in clinical trials

GSK-690693RequestCatalog# A-1020   

        GSK-690693 is an inhibit of Akt kinases 1, 2, and 3

GW-572016RequestCatalog# A-1021   

        GW-572016 is an inhibitor of EGFR(Ki=3nM),ErbB-2(Ki=13nM),ErbB-4(Ki=347nM)

HSP-990RequestCatalog# A-1144   

        HSP990 is an orally available Hsp90 inhibitor

INC-280RequestCatalog# A-1145   

        Oral, highly selective c-Met receptor tyrosine kinase (RTK) inhibitor

INC-424RequestCatalog# A-1146   

        An oral, Janus kinase (JAK) inhibitor selective for JAK1 and JAK2

INCB-018424RequestCatalog# A-1134   

        INCB018424 is an oral, selective JAK inhibitor

INK-1117RequestCatalog# A-1132   

        INK-1117 is an orally-available PI3K汐-isoform inhibitor.

INK-1197RequestCatalog# A-1133   

        INK-1197 is an orally available dual delta/gamma-specific inhibitor of PI3K.

INK-128RequestCatalog# A-1023   

        INK-128 is an mTORC1/C2 inhibitor

IPI-269609RequestCatalog# A-1063   

        An orally bioavailable small-molecule inhibitor of Hedgehog

IPI-926RequestCatalog# A-1062   

        IPI-926 is a novel, potent, orally-available small molecule inhibitor of the Hedgehog pathway.

Iressa (Gefitinib)RequestCatalog# A-1024   

        Iressa is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which was approved for cancer treatment by FDA.

ITF-2357RequestCatalog# A-1186   

        ITF2357 is a noverl HDAC inhibitor.

JNJ-26481585RequestCatalog# A-1162   

        JNJ-26481585 is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of HDAC with potential antineoplastic activity.

JNJ-38877605RequestCatalog# A-1119   

        JNJ-38877605 is an orally available selective c-Met inhibitor in clinical.

KRP-203RequestCatalog# A-1213   

        KRP-203 is an EDG3 inhibitor in clinical trials.

KU-0063794RequestCatalog# A-1124   

        Selective inhibitor of mammalian target of rapamycin (mTOR)

KW-2478RequestCatalog# A-1115   

        KW-2478 is an Hsp90 inhibitor in clinical trials.

LBH-589RequestCatalog# A-1025   

        LBH-589 is a highly potent deacetylase inhibitor shown to impede multiple pathways implicated in cancer associated with cutaneous T-cell lymphoma and other challenging malignancies.

LCL-161RequestCatalog# A-1147   

        Promoting cancer cell death by deactivating inhibitor of apoptosis proteins (IAPs)

LDK-378RequestCatalog# A-1189   

        LDK-378 is an ALK inhibitor.

LY-2784544RequestCatalog# A-1170   

        LY2784544 is a small molecule selective mutant JAK2 kinase inhibitor.

LY-2874455RequestCatalog# A-1198   

        LY2874455 is a Novel FGF/FGFR Inhibitor.

LY2801653RequestCatalog# A-1182   

        LY2801653 is a c-Met inhibitor.

MEK-162 (ARRY-162)RequestCatalog# A-1128   

        MEK-162(ARRY-162) is an MEK inhibitor in clinical trials

MGCD-0103 (Mocetinostat)RequestCatalog# A-1106   

        MGCD-0103 (Mocetinostat) is HDAC inhibitor, and inhibits Class 1 isoforms of HDAC,specifically HDAC 1(IC50=0.15umol/l), 2(IC50=0.29umol/l) and3(IC50=1.66umol/l).

MIDOSTAURIN(PKC412)RequestCatalog# A-1148   

        PKC412 (midostaurin) is an oral multi-targeted kinase inhibitor

MK-1775RequestCatalog# A-1117   

        MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.

MK-2206RequestCatalog# A-1026   

        MK-2206 is an oral potent allosteric Akt inhibitor (IC50=8nM,2nM,65nM for Akt1 Akt2 and Akt3 resp.)

MK-470RequestCatalog# A-1199   

        MK-470 is an SYK inhibitor.

MK-4827RequestCatalog# A-1092   

        MK-4827 is a PARP inhibitor in clinical trials

MK-8033RequestCatalog# A-1107   

        MK-8033 is a c-MET inhibitor in clinical trials

MK-8669 (AP-23573, Deforolimus)RequestCatalog# A-1004   

        MK-8669 (AP-23573, Deforolimus) is an mTOR inhibitor.

MLN-2480RequestCatalog# A-1192   

        MLN -2480 is a pan Raf inhibitor in chinical trials.

MLN-4924RequestCatalog# A-1139   

        MLN4924 is a novel NAE inhibitor, on blood and skin.

MLN-8237RequestCatalog# A-1123   

        MLN8237 is a second-generation, selective AAK inhibitor.

MLN-9708RequestCatalog# A-1097   

        MLN-9708 is a Proteasome inhibitor in clinical trials

MS-275RequestCatalog# A-1059   

        MS-275 is a histone deacetylase inhibitor.

NBI-0052RequestCatalog# A-1096   

        NBI-0052 is a Proteasome inhibitor in clinical trials

NMS-1116354RequestCatalog# A-1073   

        NMS-1116354 is a CDC7 inhibitor in clinical trials.

NMS-1286937RequestCatalog# A-1094   

        NMS-1286937 is a PLK inhibitor in clinical trials

NPI-0052RequestCatalog# A-1141   

        NPI-0052 is a novel proteasome inhibitor.

NV-128RequestCatalog# A-1027   

        NV-128 is an mTOR inhibitor

NVP-AUY-922RequestCatalog# A-1111   

        NVP-AUY922 is a novel Hsp90 inhibitor

NVP-LDE-225 (free base)RequestCatalog# A-1126   

        NVP-LDE-225 is an Hedgehog inhibitor in clinical trials

NVP-TAE-684RequestCatalog# A-1046   

        NVP-TAE-684 is a selective NPM-ALK inhibitor with IC50 values between 2 and 10 nM. Treatment of TAE684 resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest in cancer cells.

Obatoclax (GX15-070)RequestCatalog# A-1022   

        Obatoclax (GX15-070) is an inhibit of the Bcl-2.

OPB-31121RequestCatalog# A-1104   

        OPB-31121 is a Stat3 in clinical trials

OSI-027RequestCatalog# A-1065   

        OSI-027 is an orally bioavailable mTORC1/C2 kinase inhibitor with anti-tumor activity.

OSI-906RequestCatalog# A-1058   

        OSI-906 is a potent, selective orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R).

OSU-03012RequestCatalog# A-1209   

        OSU-03012 is a PDK1 inhibitor in clinical trials.

P-1446A-05RequestCatalog# A-1074   

        P-1446A-05 is a CDK inhibitor in clinical trials.

P-276-00RequestCatalog# A-1076   

        P-276-00 is a CDK inhibitor in clinical trials

PCI-24781RequestCatalog# A-1081   

        PCI-24781 is a HDAC inhibitor in clinical trials

PCI-32765RequestCatalog# A-1201   

        PCI-32765 is a BTK inhibitor in clinical trials.

PD-0332991RequestCatalog# A-1030   

        PD-0332991 is an orally available Cdk inhibitor.

PF-00562271RequestCatalog# A-1080   

        PF-00562271 is a FAK inhibitor in clinical trials

PF-01367338RequestCatalog# A-1093   

        PF-01367338 is a PARP inhibitor in clinical trials

PF-02341066RequestCatalog# A-1031   

        PF-02341066 is a potent and selective dual ALK and c-MET inhibitor in clinical trials.

PF-03758309RequestCatalog# A-1091   

        PF-03758309 is a PAK4 inhibitor in clinical trials

PF-04217903RequestCatalog# A-1114   

        PF-04217903 is a c-MET inhbitor

PF-04554878RequestCatalog# A-1079   

        PF-04554878 is a FAK inhibitor in clinical trials

PF-04691502RequestCatalog# A-1101   

        PF-04691502 is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.

PF-05212384 (PKI-587)RequestCatalog# A-1071   

        PF-05212384 (PKI-587) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.

PF4989216RequestCatalog# A-1184   

PHA-665752RequestCatalog# A-1032   

        PHA-665752 is a potent, selective and ATP-competitive inhibitor of c-MET kinase

PHA-848125ACRequestCatalog# A-1204   

        PHA-848125AC is an orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity.

PKI-587(PF-05212384)RequestCatalog# A-1071   

        PF-05212384 (PKI-587) is a potent and selective dual PI3K/mTOR inhibitor in clinical trials.

PLX-4032(RG7204, RO5185426, Vemurafenib)RequestCatalog# A-1130   

        PLX-4032 is a B-Raf inhibitor

PLX-4720RequestCatalog# A-1131   

        PLX-4720 is a B-Raf inhibitor.

PLX108-01RequestCatalog# A-1203   

        PLX108-01 (PLX3397) is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.

Pp-242RequestCatalog# A-1033   

        Pp-242 is an mTORC1/C2 inhibitor

PR-171(Carfilzomib)RequestCatalog# A-1098   

        PR-171 is a Proteasome inhibitor in clinical trials

PTC-124RequestCatalog# A-1034   

PX-866RequestCatalog#    

         PX-866 is a PI3K inhibitor in clinical trials

R-935788RequestCatalog# A-1200   

        R-935788 is an SYK inhibitor.

RAF-265RequestCatalog# A-1149   

        An oral, highly selective RAF and VEGFR kinase inhibitor

Rapamycin (Sirolimus)RequestCatalog# A-1035   

        Rapamycin is a mammalian target of rapamycin (mTOR C1) inhibitor

RDEA-119 (BAY-869766)RequestCatalog# A-1036   

        RDEA-119 (BAY-869766) is a potent and highly selective MEK Inhibitor

RDEA-427RequestCatalog# A-1037   

RDEA-436RequestCatalog# A-1038   

        RDEA-436 is a novel, potent, broadly active MEK inhibitor, with a low EC50 in human serum

RDEA-594RequestCatalog# A-1039   

RDEA-806RequestCatalog# A-1040   

Regorafenib (BAY73-4506)RequestCatalog# A-1112   

        Regorafenib (BAY73-4506) is an oral multikinase inhibitor, including B-Raf (IC50, 69 nM), c-KIT (IC 50, 17 nM), VEGFR2 (IC50, 40nM)

ResminostatRequestCatalog# A-1190   

        Resminostat is an HDAC inhibitor in clinicals.

RO-4987655RequestCatalog# A-1084   

        RO-4987655 is a MEK inhibitor in clinical trials

RO-5126766RequestCatalog# A-1085   

        RO-5126766 is a dual Raf and MEK inhibitor in clinical trials.

RO-5185426/PLX-4032RequestCatalog# A-1150   

        RO5185426 (also known as PLX4032) is a B-RAF inhibitor.

RO-5212054/PLX-3603RequestCatalog# A-1151   

        RO-5212054/PLX-3603 is a B-Raf inhibitor.

RO-5323441RequestCatalog# A-1152   

        RO-5323441

SAHA (Vorinostat)RequestCatalog# A-1041   

        SAHA is an HDAC inhibitor and shows IC 50 of 10 nM (HDAC-1) and 300 nM (rat liver HDAC)

SB-1518RequestCatalog# A-1136   

        SB-1518 is a JAK2 inhibitor.

SB-216763RequestCatalog# A-1042   

SB-431542RequestCatalog# A-1043   

        SB-431542 is a potent and selective inhibitor of transforming growth factor superfamily type I activin receptor-like kinase (ALK) receptors.

SB-939RequestCatalog# A-1185   

        SB-939 is a novel histone deacetylase (HDAC) inhibitor.

SCH-727965RequestCatalog# A-1075   

        SCH-727965 is a CDK inhibitor in clinical trials

SCH-900353RequestCatalog# A-1191   

        SCH-900353 is an ERK1 inhibitor.

SCH-900776RequestCatalog# A-1202   

        SCH 900776 is a potent and selective CHK1 inhibitor with IC50 of 3 nM, 0.16 and 1.5 米M for CHK1, CDK2 and CHK2, respectively.

SGI-1776RequestCatalog# A-1102   

        SGI-1776 is a PIM kinase inhibitor in clinical trials

SGX-523RequestCatalog# A-1060   

        SGX523 is an orally bioavailable Met inhibitor

SilmitasertibRequestCatalog# A-1211   

        Silmitasertib is an orally bioavailable small-molecule inhibitor of CK2 with potential antineoplastic activity.

Sorafenib (BAY 43-9006)RequestCatalog# A-1044   

SR-13668RequestCatalog# A-1206   

        SR13668, an orally active Akt/PKB pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies.

STA-9090RequestCatalog# A-1179   

        STA-9090 is an HSP-90 inhibitor.

SutentRequestCatalog# A-1045   

        Sunitinib (marketed as Sutent, and previously known as SU11248) is an oral RTK inhibitor that was approved by the FDA

TAK-441RequestCatalog# A-1172   

        TAK441 is a Hedgehog inhibitor.

TAK-700RequestCatalog# A-1193   

        TAK-700 is an oral, selective, non-steroidal androgen synthesis inhibitor of the 17,20 lyase in clinical trials.

TalarozoleRequestCatalog# A-1212   

        Talarozole is a Cyp26 inhibitor in clinical trials.

TamoxifenRequestCatalog# A-1047   

        Tamoxifen is an antagonist of the estrogen receptor in breast tissue.

Tarceva (Erlotinib, OSI-774)RequestCatalog# A-1048   

        Tarceva is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which was approved for cancer treatment by FDA.

TG-101348RequestCatalog# A-1140   

        TG-101348 is a potent, highly selective JAK2 inhibitor

TG-2RequestCatalog# A-1208   

        TG-2 is an ERK/Flt3/Jak2 inhibitor in clinical trials.

TGX-221RequestCatalog# A-1050   

        TGX-221 is a cell-permeable morpholino-pyrimidinone compound that acts as a reversible, ATP-competitive, selective, and highly potent inhibitor of PI 3-Kb

TKI-258(CHIR-258, Dovitinib)RequestCatalog# A-1129   

        TKI258 is a novel FGFR/PDGFR/VEGFR inhibitor

Tubastatin ARequestCatalog# A-1159   

        Tubastatin A is a potent and selective HDAC6 (histone deacetylase 6) inhibitor.

VX-11eRequestCatalog# A-1195   

        VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK2.

WYE-354RequestCatalog# A-1051   

        WYE-354 is an mTOR inhibitor

XL-019RequestCatalog# A-1137   

        XL019 is a potent JAK2 inhibitor (IC50 = 2 nM)

XL-138RequestCatalog# A-1173   

XL-147RequestCatalog# A-1052   

        XL-147 is a PI3k inhibitor

XL-184RequestCatalog# A-1089   

        XL-184 is a c-Met inhibitor in clinical trials

XL-518RequestCatalog# A-1180   

        XL-518 is a potent selective orally bioavailable MEK1 inhibitor.

XL-765RequestCatalog# A-1068   

        XL-765 is a PI3K/mTOR inhibitor in clinical trials;

Y-39983RequestCatalog# A-1210   

        Y-39983 is a novel Rock1 inhibitor in clinical trials.

YM-155RequestCatalog# A-1061   

        YM-155 is a novel small molecule survivin inhibitor.

ZM-447439RequestCatalog# A-1054   

ZSTK-474RequestCatalog# A-1055   

        ZSTK-474 is a PI3Ka/b/g/d inhibitor

*Note: These products are for research purposes only, not for human consumption.